Companies

Novo Nordisk

Novo Nordisk is the global leader in diabetes and obesity care, pioneering GLP-1 therapies such as semaglutide. It funds extensive metabolic-disease research through the Novo Nordisk Foundation and collaborates with Danish and international universities on protein engineering.

Details

Industry

Biopharma

R&D Spend

$5.2B